Sichuan Baili Pharmaceutical Co., Ltd.

This is an early-stage study to test the safety and initial effects of a new experimental drug called GNC-077 in people with advanced breast cancer or other solid tumors that have spread. The main goal is to find a safe dose and see how the body processes the drug. Researchers wi…

This study is testing whether a new drug called BL-M07D1, given with or without pertuzumab, works better than standard chemotherapy before surgery for HER2-positive breast cancer. The trial will involve 120 women with stage 2 or 3 breast cancer who haven't had previous cancer tre…

This study is testing two experimental drugs, BL-B01D1 and SI-B003, to see if they can help control advanced cervical and other gynecological cancers that have returned or spread. Researchers will give the drugs separately and together to about 130 patients to find the most effec…

This is the first human study of an experimental drug called BL-M17D1 for people with advanced breast cancer and other solid tumors. The main goals are to find the safest dose and see how the body processes the drug. Researchers will also look for early signs that the drug might …

This study is testing whether a new drug called BL-M07D1 works better than standard chemotherapy for people with advanced HER2-low breast cancer that has returned or spread. It will involve about 566 participants who will be randomly assigned to receive either the new drug or a c…

This early-stage study is testing a new experimental drug called GNC-038 in adults whose non-Hodgkin's lymphoma has come back or hasn't responded to other treatments. The main goals are to find a safe dose and see if the drug can help control the cancer. The drug is a special ant…

This study is testing whether adding two new drugs (SI-B001 and SI-B003) to standard chemotherapy works better for people with advanced head and neck cancer that has returned or spread. The trial will enroll 60 adults to see if this combination helps shrink tumors and is safe. Re…

This is an early-stage study testing a new drug called BL-M24D1 in patients with advanced non-small cell lung cancer and other solid tumors. The main goals are to find a safe dose, check how the body processes the drug, and look for early signs that it might help control the canc…

This is an early-stage study testing a new drug called BL-B16D1 in people with advanced head and neck cancer or other solid tumors that have returned or spread. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it migh…

This early-stage study is testing a new drug called BL-M17D1 in adults with advanced gastrointestinal cancers and other solid tumors that have a specific marker called HER2. The main goal is to find the safest dose and see how the body processes the drug. Researchers will also ch…

This early-stage trial is testing a new drug called BL-M11D1 in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goals are to find the safest dose and check for side effects. Researchers will also gather early informatio…

This study is testing whether a new drug called BL-M07D1 works better when combined with an existing immunotherapy (pembrolizumab) for people with a specific type of advanced lung cancer that has too much HER2 protein. It will involve about 80 adults whose cancer has spread and c…

This study is testing whether a new drug called BL-M07D1 works better than standard chemotherapy for people with advanced HER2-positive stomach or gastroesophageal cancer. It's for patients whose cancer has continued to grow despite their first round of treatment. The main goals …

This study is testing a new drug called BL-B01D1 for people with advanced solid tumors, including gynecological cancers that have returned or spread. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for adults whose cancer has p…

This study is testing two new drugs, SI-B001 and SI-B003, for people with advanced head and neck cancer that has spread or cannot be removed by surgery. The first part finds the safest and most effective dose. The second part checks how well the drug combination works to shrink t…

This is an early-stage study to test the safety and find the right dose of a new drug called BL-M08D1 for adults with advanced lymphoid cancers that have come back or stopped responding to standard treatments. Researchers will enroll about 22 participants to see how the body hand…

This study is testing an experimental drug called BL-B01D1 in patients with advanced solid tumors that have spread or can't be surgically removed. The trial aims to find the right dose and see if the drug can shrink tumors in people who have already tried standard treatments. Res…

This study is testing two new drugs, BL-B01D1 and SI-B003, given alone and together for people with advanced head and neck cancer that has returned or spread. The main goals are to see if the treatments shrink tumors and are safe for patients. It will include about 186 adults who…

This is an early-stage study to test the safety and initial effects of a new experimental drug called GNC-039 in adults with advanced solid tumors that have returned or spread after standard treatments. The main goals are to find a safe dose and see what side effects occur. Resea…

This is an early-stage study testing a new drug called BL-M24D1 in patients with advanced gastrointestinal cancers and other solid tumors that have spread. The main goal is to find the safest dose and see how the body processes the drug. Researchers will also look for early signs…

This study is testing a new combination of drugs (BL-B01D1, pembrolizumab, and sometimes bevacizumab) for women with advanced cervical or endometrial cancer that has returned or spread. The goal is to see if this combination can shrink tumors and control the disease better than c…

This is an early-stage study testing a new drug called BL-B01D1 for people with advanced solid tumors that have spread or cannot be cured with standard treatments. The main goals are to find the safest dose, check how the body processes the drug, and look for early signs that it …

This study is testing a new drug, SI-B003, given alone or combined with another drug called BL-B01D1, for people with advanced HER2-negative breast cancer that has spread or come back and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and …

This is a very early study to test the safety and find the right dose of a new drug called BL-B01D1. It is for adults with advanced breast cancer or other solid tumors that have spread or cannot be removed by surgery and have few treatment options left. The main goals are to see …

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced lung cancer or throat cancer that has spread. The main goals are to see if the treatment can shrink tumors and to determine the safest and most effective dose. It will involve about 121…

This is a first-in-human study to test the safety and early effectiveness of a new radioactive drug called Lutetium BL-ARC001. It is for adults with advanced gastrointestinal cancers or other solid tumors that have spread or cannot be surgically removed. The main goals are to fin…

This study is testing two new drug approaches for people with advanced bladder cancer and other solid tumors that have stopped responding to standard treatments. It will enroll 52 participants to see if either a single drug (SI-B003) or a combination of two drugs (BL-B01D1+SI-B00…

This study is testing a new combination of two drugs, called SI-B001 and SI-B003, for people with advanced non-small cell lung cancer that has spread. The first part aims to find a safe dose, and the second part will see how well the drug combo works, either alone or with standar…

This early-stage trial is testing a new experimental drug called GNC-035 in adults with non-Hodgkin's lymphoma or other blood cancers that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug shows early signs of fighti…

This is a first-in-human study to test the safety and find the right dose of a new drug called BL-B01D1. It is for adults with advanced gastrointestinal or other solid tumors that have stopped responding to standard treatments. The main goals are to see how much of the drug the b…

This study is testing a new drug called BL-M07D1 for women with advanced gynecologic cancers that have returned or spread and express a protein called HER2. The trial aims to find the safest and most effective dose and see how well the drug shrinks tumors. It is for patients whos…

This is a first-in-human study to test the safety and side effects of a new drug called BL-B16D1. It will involve adults with advanced breast cancer or other solid tumors that have spread and cannot be removed by surgery, and who have run out of standard treatment options. The ma…

This early-stage study is testing a new radioactive drug called Lutetium-177 BL-ARC001 in people with advanced lung, breast, head/neck, and other solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose, see how the body process…

This is the first human study of an experimental antibody called GNC-077 for people with advanced non-small cell lung cancer and other solid tumors. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will enroll about 20 participants …

This is the first study in people to test a new drug called BL-M14D1 for advanced cancers that have spread or cannot be removed by surgery. The main goal is to find a safe dose and see how the body processes the drug in about 22 adults with certain cancers, including small cell l…

This is a first-in-human study to test the safety and determine the right dose of an experimental drug called BL-B16D1 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The trial will enroll patients who have already tried standard treatments …

This is a first-in-human study to test the safety and find the right dose of a new drug called BL-M07D1. It is for adults with advanced digestive tract cancers (like stomach or colon cancer) or other solid tumors that have spread and have stopped responding to standard treatments…

This study is testing whether a new drug called BL-B01D1 works better when combined with an existing immunotherapy (PD-1 antibody) to control advanced cancers that have spread. It will involve about 570 adults with non-small cell lung cancer, nasopharyngeal cancer, or other solid…

This study is testing three different treatment approaches for people with advanced cancers of the esophagus, stomach, colon, and other digestive organs. Researchers want to see if new drug combinations can shrink tumors and control the disease better than current options. The tr…

This large, late-stage trial is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced bladder cancer that has come back or spread. It is for patients whose cancer has continued to grow despite receiving two common types of tre…

This study is comparing a new targeted drug called BL-M07D1 against standard chemotherapy for people with advanced lung cancer that has a specific genetic change called a HER2 mutation. It aims to see if the new drug can better control the cancer and help people live longer witho…

This study is testing two new drugs, BL-B01D1 and SI-B003, given alone and together, for people with advanced small cell lung cancer that has spread. The main goal is to see if these treatments shrink tumors and are safe for patients. It will enroll about 100 adults whose cancer …

This is an early-stage study testing a new drug called BL-M07D1 for people with advanced breast cancer and other solid tumors that have spread or cannot be removed by surgery. The main goal is to find a safe dose and check for side effects in a small group of patients whose cance…

This is an early-stage study testing a new drug called BL-M24D1 in patients with advanced head and neck cancer or other solid tumors. The main goals are to find a safe dose, see how the drug moves through the body, and check for any early signs that it might help shrink tumors. R…

This large study is testing whether a new drug called BL-M07D1 works better than the current standard treatment (T-DM1) for people with a specific type of breast cancer. It's for women with HER2-positive breast cancer who still have some cancer cells left after their initial chem…

This study is testing a new three-drug combination for people with advanced kidney cancer that has spread. It aims to see if adding a new drug called BL-B01D1 to standard treatments can better shrink tumors and control the disease. The trial will enroll about 260 patients to meas…

This large, late-stage study aims to see if adding a new investigational drug (BL-B01D1) to a standard targeted therapy (osimertinib) works better than the standard therapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation…